In fiscal 2019, the FDA approved a whopping 1,171 generics. Still, a study found the approvals aren't helping in certain high-cost market segments.

BioMarin is collaborating again with Believe Limited for an arts program to support people with hemophilia.

AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

How much are lawsuits hurting J&J's brand? The New Jersey drugmaker has lost half a billion dollars in brand value over the past year, a report says.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.